Asia Pacific Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity

Asia Pacific biodefense market will grow by 7.8% annually over 2020-2030 with a total addressable market cap of $15.8 billion

Asia Pacific biodefense market will grow by 7.8% annually over 2020-2030 with a total addressable market cap of $15.8 billion in the fast-growing region despite the COVID-19 impact. Biodefense is referred to the measures taken to restore biosecurity of a group of organisms that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care.The release of pathogenic agents such as anthrax or smallpox, biological toxins, chemical weapons such as nerve gas, or radioactive substances caused public threats in the past. In order to prevent such outbreaks, the government has planned various strategies. The growing prevalence of infectious diseases, such as coronavirus, Ebola and zika virus, is likely to boost the investments in the field of biodefense, thereby driving the Biodefense Market growth.The growth of the Biodefense Market is driven by factors such as the favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM in the Asia Pacific region. However, low R&D funding by government in developing and underdeveloped economies is likely to restrain the market growth to a certain extent. The growing threat of terrorism, coupled with continually rising tension between nations across the globe, is one of the key factors driving the growth of the market. Furthermore, the increasing defense expenditure by the governments of several nations to improve both internal and external security is also providing a boost to the market growth. In line with this, there is widespread adoption of innovative technologies, such as gene chips, for the detection of pathogens in the fields of nanotechnology, forensics and biodefense-related drug development. Additionally, government agencies are recognizing various chemical, biological, nuclear and radiological threats and are developing medical countermeasures to minimize the adverse effects of these attacks. Apart from this, there is an increasing awareness regarding synthetic biology for improving agricultural yields, which is also creating a positive impact on the market growth. Apart from these, due to the recent COVID-19 pandemic, there has been an increasing demand for medical measures and threat detection procedures, which is also providing a boost to the market growth. Other factors, including extensive research and development (R&D) in the field of biotechnology, along with the availability of advanced biothreat detection devices, are projected to drive the market further. Some major findings of the biodefense market include the realisation of rising risk of infectious disease prevalence is expected to spur the industry statistics.Growing adoption of gene chips for pathogen detection in the field of forensics, nanotechnology and biodefense-related drug development will foster the market trends. Along with this increasing awareness regarding bioterrorism attacks in developed economies will significantly fuel the business outlook. Also rising R&D activities in the field of biotechnology and the availability of advanced biothreat detection devices, are set to enhance the market share. The emergence of COVID-19 boosts the demand for medical measures and threat detection procedures. Additionally, there is an increased production of vaccine and high demand for detection kits and quick diagnostics. The anthrax segment accounted for the largest market share in the Biodefense Market in Asia Pacific. The segment is expected to continue its dominance over the forecast period owing to increasing funding by the governments of other countries to develop and stockpile adequate vaccines against anthrax mainly through a variety of initiatives in Asian countries, such as safe and security initiative , Special Measures Act for Pandemic preparedness, Civilian Protection Act and the Defense Research and Development Establishment (DRDE).


Impact of Covid-19

The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Many countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products. 
Impact of the coronavirus (COVID-19) pandemic is expected to drive the growth of the global biodefense market during the forecast period, owing to the raising awareness between government agencies against bioterrorism or biological warfare amongst the consequences of COVID-19 pandemic. For instance, in April 2021, the Counter Terrorism Preparedness Network (CTPN) launched a detailed report titled ‘Bioterrorism: Applying the Lens of COVID-19’. The report's main goal was to discuss the threat of bioterrorism in the light of COVID-19 and the advancements in technology and biosciences. The report also suggested that it is essential that relevant industries makes recommendations to the government authorities to improve their preparedness and capabilities for bioterrorism and, as a result prepare them for public health crises. These factors are expected to support the growth of global biodefense market.


Highlighted with 32 tables and 40 figures, this 108-page report “Asia Pacific Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific biodefense market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. 

In-depth qualitative analyses include identification and investigation of the following aspects:
   • Market Structure 
   • Growth Drivers 
   • Restraints and Challenges
   • Emerging Product Trends & Market Opportunities
   • Porter’s Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Country. 


By Product type  
     • Vaccines
            • Anthrax
            • Smallpox
            • Botulism
            • Nuclear/Radiation
            • E-Bola
            • Zika
            • Other Vaccines
     • Biothreat Detection Devices
            • Detectors/Triggering Devices
            • Assays and Reagents
            • Samplers
            • Identifiers
     •Antibiotics
     • Masks
     • Other Products 


By Sales Channel
     • Online Sales
     • Offline Sales

By Application
     • Military
     • Civilian

By Geography
     • Japan
     • China
     • South Korea
     • Australia
     • India
     • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

For each aforementioned country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Sales Channel, and Application over the forecast years is also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific biodefense market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request): 
Achaogen, Inc., Alexeter Technologies LLC, Alnylam Pharmaceuticals, Inc., Altimmune, Inc., Bavarian Nordic AS, BioFactura, Inc., Cleveland Biolabs, Inc., Dynavax Technologies Inc, Dynport Vaccine Company LLC (DVC), Elusys Therapeutics, Inc., Emergent BioSolutions Inc, General Dynamics Corp., GlaxoSmithKline Plc, Ichor Medical Systems, Mediimmune (AstraZeneca), Nanotherapeutics, Inc., Ology Bioscience, PathSensors Inc, Pluristem Therapeutics, Sanofi Pasteur Ltd., SIGA Technologies, Inc., Soligenix, Inc., Xoma Corporation, 

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Table of Contents

  • 1. Introduction
  • 1.1. Industry Definition and Research Scope
  • 1.1.1. Industry Definition
  • 1.1.2. Research Scope
  • 1.2. Research Methodology
  • 1.2.1. Overview of Market Research Methodology
  • 1.2.2. Market Assumption
  • 1.2.3. Secondary Data
  • 1.2.4. Primary Data
  • 1.2.5. Data Filtration and Model Design
  • 1.2.6. Market Size/Share Estimation
  • 1.2.7. Research Limitations
  • 1.3. Executive Summary
  • 2. Market Overview and Dynamics
  • 2.1. Market Size and Forecast
  • 2.2. Major Growth Drivers
  • 2.3. Market Restraints and Challenges
  • 2.4. Emerging Opportunities and Market Trends
  • 2.5. Porter’s Fiver Forces Analysis
  • 3. Segmentation of Asia Pacific Market by Product
  • 3.1. Market Overview by Product
  • 3.2. Vaccines
  • 3.2.1. Anthrax
  • 3.2.2. Smallpox
  • 3.2.3. Botulism
  • 3.2.4. Nuclear/Radiation
  • 3.2.5. E-Bola
  • 3.2.6. Zika
  • 3.2.7. Other Vaccines
  • 3.3. Biothreat Detection Devices
  • 3.4. Antibiotics
  • 3.5. Masks
  • 3.6. Other Products
  • 4. Segmentation of Asia Pacific Market by Sales Channel
  • 4.1. Market Overview by Sales Channel
  • 4.2. Online Sales
  • 4.3. Offline Sales
  • 5. Segmentation of Asia Pacific Market by Application
  • 5.1. Market Overview by Application
  • 5.2. Military
  • 5.3. Civilian
  • 6. Asia-Pacific Market 2019-2030 by Country
  • 6.1. Overview of Asia-Pacific Market
  • 6.2. Japan
  • 6.3. China
  • 6.4. Australia
  • 6.5. India
  • 6.6. South Korea
  • 6.7. Rest of APAC Region
  • 7. Competitive Landscape
  • 7.1. Overview of Key Vendors
  • 7.2. New Product Launch, Partnership, Investment, and M&A
  • 7.3. Company Profiles
  • 7.3.1. Achaogen, Inc.
  • 7.3.2. Alexeter Technologies LLC
  • 7.3.3. Alnylam Pharmaceuticals, Inc.
  • 7.3.4. Altimmune, Inc.
  • 7.3.5. Bavarian Nordic AS
  • 7.3.6. BioFactura, Inc.
  • 7.3.7. Cleveland Biolabs, Inc.
  • 7.3.8. Dynavax Technologies Inc
  • 7.3.9. Dynport Vaccine Company LLC (DVC)
  • 7.3.10. Elusys Therapeutics, Inc.
  • 7.3.11. Emergent BioSolutions Inc
  • 7.3.12. General Dynamics Corp.
  • 7.3.13. GlaxoSmithKline Plc
  • 7.3.14. Ichor Medical Systems
  • 7.3.15. Mediimmune (AstraZeneca)
  • 7.3.16. Nanotherapeutics, Inc.
  • 7.3.17. Ology Bioscience
  • 7.3.18. PathSensors Inc
  • 7.3.19. Pluristem Therapeutics
  • 7.3.20. Sanofi Pasteur Ltd.
  • 7.3.21. SIGA Technologies, Inc.
  • 7.3.22. Soligenix, Inc.
  • 7.3.23. Xoma Corporation
  • 8. Investing in Asia Pacific Market: Risk Assessment and Management
  • 8.1. Risk Evaluation of Asia Pacific Market
  • 8.2. Critical Success Factors (CSFs)
  • Related Reports and Products

List of Tables

Table 1. Snapshot of Asia Pacific Biodefense Market, 2020-2030
Table 2. Main Product Trends and Market Opportunities in Asia Pacific Biodefense Market
Table 3. Asia Pacific Biodefense Market by Product, 2020-2030, $ mn
Table 4. Asia Pacific Biodefense Market: Vaccines by Application, 2020-2030, $ mn
Table 5. List of Biodefense Vaccine Pipelines
Table 6. Asia Pacific Biodefense Market: Vaccines Biothreat Detection Devices by Type, 2020-2030, $ mn
Table 7. Asia Pacific Biodefense Market by Sales Channel, 2020-2030, $ mn
Table 8. Asia Pacific Market by Application, 2020-2030, $ mn
Table 9. APAC Biodefense Market by Country, 2020-2030, $ mn
Table 10. Japan Biodefense Market by Product, 2020-2030, $ mn
Table 11. Japan Biodefense Market by Sales Channel, 2020-2030, $ mn
Table 12. Japan Biodefense Market by Application, 2020-2030, $ mn
Table 13. China Biodefense Market by Product, 2020-2030, $ mn
Table 14. China Biodefense Market by Sales Channel, 2020-2030, $ mn
Table 15. China Biodefense Market by Application, 2020-2030, $ mn
Table 16. Australia Biodefense Market by Product, 2020-2030, $ mn
Table 17. Australia Biodefense Market by Sales Channel, 2020-2030, $ mn
Table 18. Australia Biodefense Market by Application, 2020-2030, $ mn
Table 19. India Biodefense Market by Product, 2020-2030, $ mn
Table 20. India Biodefense Market by Sales Channel, 2020-2030, $ mn
Table 21. India Biodefense Market by Application, 2020-2030, $ mn
Table 22. South Korea Biodefense Market by Product, 2020-2030, $ mn
Table 23. South Korea Biodefense Market by Sales Channel, 2020-2030, $ mn
Table 24. South Korea Biodefense Market by Application, 2020-2030, $ mn
Table 25. Biodefense Market in Rest of APAC by Country, 2020-2030, $ mn
Table 26. Achaogen, Inc.: Company Snapshot
Table 27. Achaogen, Inc.: Business Segmentation
Table 28. Achaogen, Inc.: Product Portfolio
Table 29. Achaogen, Inc.: Revenue, 2019-2021, $ mn
Table 30. Achaogen, Inc.: Recent Developments
Table 31. Risk Evaluation for Investing in Asia Pacific Market, 2020-2030
Table 32. Critical Success Factors and Key Takeaways

List of Figures

Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2030
Figure 5. Asia Pacific Biodefense Market, 2020-2030, $ mn
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Biodefense Market
Figure 7. Primary Restraints and Impact Factors of Asia Pacific Biodefense Market
Figure 8. Investment Opportunity Analysis
Figure 9. Porter’s Fiver Forces Analysis of Asia Pacific Biodefense Market
Figure 10. Breakdown of Asia Pacific Biodefense Market by Product, 2020-2030, % of Sales Revenue
Figure 11. Asia Pacific Addressable Market Cap in 2020-2030 by Product, Value ($ mn) and Share (%)
Figure 12. Asia Pacific Biodefense Market: Vaccines, 2020-2030, $ mn
Figure 13. Asia Pacific Biodefense Market: Anthrax, 2020-2030, $ mn
Figure 14. Asia Pacific Biodefense Market: Smallpox, 2020-2030, $ mn
Figure 15. Asia Pacific Biodefense Market: Botulism, 2020-2030, $ mn
Figure 16. Asia Pacific Biodefense Market: Nuclear/Radiation, 2020-2030, $ mn
Figure 17. Asia Pacific Biodefense Market: E-Bola, 2020-2030, $ mn
Figure 18. Asia Pacific Biodefense Market: Zika, 2020-2030, $ mn
Figure 19. Asia Pacific Biodefense Market: Other Vaccines, 2020-2030, $ mn
Figure 20. Asia Pacific Biodefense Market: Biothreat Detection Devices, 2020-2030, $ mn
Figure 21. Asia Pacific Biodefense Market: Antibiotics, 2020-2030, $ mn
Figure 22. Asia Pacific Biodefense Market: Masks, 2020-2030, $ mn
Figure 23. Asia Pacific Biodefense Market: Other Products, 2020-2030, $ mn
Figure 24. Breakdown of Asia Pacific Biodefense Market by Sales Channel, 2020-2030, % of Sales Revenue
Figure 25. Asia Pacific Addressable Market Cap in 2020-2030 by Sales Channel, Value ($ mn) and Share (%)
Figure 26. Asia Pacific Biodefense Market: Online Sales, 2020-2030, $ mn
Figure 27. Asia Pacific Biodefense Market: Offline Sales, 2020-2030, $ mn
Figure 28. Breakdown of Asia Pacific Market by Application, 2020-2030, % of Revenue
Figure 29. Asia Pacific Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)
Figure 30. Asia Pacific Biodefense Market: Military, 2020-2030, $ mn
Figure 31. Asia Pacific Biodefense Market: Civilian, 2020-2030, $ mn
Figure 32. Breakdown of APAC Biodefense Market by Country, 2020 and 2030, % of Revenue
Figure 33. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 34. Biodefense Market in Japan, 2020-2030, $ mn
Figure 35. Biodefense Market in China, 2020-2030, $ mn
Figure 36. Biodefense Market in Australia, 2020-2030, $ mn
Figure 37. Biodefense Market in India, 2020-2030, $ mn
Figure 38. Biodefense Market in South Korea, 2020-2030, $ mn
Figure 39. Biodefense Market in Rest of APAC, 2020-2030, $ mn
Figure 40. Growth Stage of Asia Pacific Biodefense Industry over the Forecast Period
Logo

Asia Pacific Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity

Contact usWe are friendly and approachable, give us a call.